Researchers at Queen Mary University of London have led the clinical development of the first non-integrase strand-transfer inhibitor (INSTI) single tablet treatment for HIV, among growing concern for ...
Black gay men face major PrEP access gaps due to cost, stigma, mistrust, and provider silence—despite high HIV impact; ...
One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and ...
Broadly neutralizing antibodies, or bnAbs, are a long‑standing goal of HIV vaccine research because they can disable many strains of the virus at once.
Combination antiretroviral therapy (ART) has transformed HIV-1 infection into a chronic condition with near-normal life expectancy. For more than two decades, the standard regimen has been a ...
More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS). The ...
More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results